The ITN trials of teplizumab (anti-CD3), alefacept (LFA3-Ig), and anti-thymocyte globulin (ATG) in type 1 diabetes (T1D) are particularly informative. This evidence concerns the gene CD58 and type 1 diabetes mellitus.